{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:01:37Z","timestamp":1785290497258,"version":"3.55.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T00:00:00Z","timestamp":1471996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161200","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T18:10:06Z","timestamp":1472062206000},"page":"e0161200","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-1699","authenticated-orcid":true,"given":"Caroline H.","family":"Chilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace S.","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ashwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","article-title":"Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection","volume":"81","author":"PN Wiegand","year":"2012","journal-title":"J Hosp Infect"},{"issue":"24","key":"ref2","first-page":"2369","article-title":"Emerging Infections Program CdST. Burden of Clostridium difficile infection in the United States","volume":"372","author":"FC Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"ref3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/cid\/cis357","article-title":"Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin","volume":"55","author":"I Figueroa","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"CP Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.24.3.206","article-title":"Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy","volume":"24","author":"BA Walters","year":"1983","journal-title":"Gut"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/jac\/dkn502","article-title":"Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model","volume":"63","author":"SD Baines","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dkt347","article-title":"Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure","volume":"69","author":"CH Chilton","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"ref8","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","author":"DW Crook","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"OA Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"TJ Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/jac\/dkv156","article-title":"Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model","volume":"70","author":"CH Chilton","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref12","article-title":"Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model","author":"GS Crowther","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jac\/dki321","article-title":"Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection","volume":"56","author":"J Freeman","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/jac\/dks243","article-title":"Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model","volume":"67","author":"CH Chilton","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/jac\/dkt160","article-title":"Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery","volume":"68","author":"CH Chilton","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1128\/AAC.04853-14","article-title":"Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model","volume":"59","author":"CN Kraus","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"e32381","DOI":"10.1371\/journal.pone.0032381","article-title":"Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts","volume":"7","author":"D Heeg","year":"2012","journal-title":"PLOS ONE"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.anaerobe.2016.04.010","article-title":"Sporulation properties and antimicrobial susceptibility in endemic and rare Clostridium difficile PCR ribotypes","volume":"39","author":"V Zidaric","year":"2016","journal-title":"Anaerobe"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.anaerobe.2013.04.003","article-title":"The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates","volume":"24","author":"PE Carlson Jr","year":"2013","journal-title":"Anaerobe"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"248 e9","DOI":"10.1016\/j.cmi.2014.09.017","article-title":"Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes","volume":"21","author":"J Freeman","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1128\/AAC.01611-12","article-title":"Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores","volume":"57","author":"CA Allen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"55","author":"F Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 9","key":"ref23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1099\/jmm.0.043687-0","article-title":"Adherence of Clostridium difficile spores to Caco-2 cells in culture","volume":"61","author":"D Paredes-Sabja","year":"2012","journal-title":"J Med Microbiol"},{"key":"ref24","unstructured":"Chilton CH, Ashwin H, Crowther GS, Longshaw CM, Wilcox MH (2014) Persistence and removal of fidaxomicin from C. difficile spores, and effects on recovery. In Proceedings of the 25th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona 2014, Abstract P0799, p176. European Society of Clinical Microbiology and Infectious Diseases, Basal, Switzerland."},{"key":"ref25","unstructured":"European Medicines Agency. DIFICLIR Public Assessment Report. 22-9-2011; Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002087\/WC500119707.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002087\/WC500119707.pdf<\/ext-link>. Accessed 6 June 2016"},{"key":"ref26","unstructured":"National Institiutes of Health. Clinical Studies Record Detail. A Phase IIIB\/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02254967\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02254967<\/ext-link>. Accessed 25 July 2016."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:41:22Z","timestamp":1589042482000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161200"}},"subtitle":[],"editor":[{"given":"Daniel","family":"Paredes-Sabja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161200","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]}}}